IQVIA Holdings, Inc. · NYSE:IQV
IQVIA — IQVIA Research Forum 2022
76 slides from IQVIA's conference presentation, October 2022
Slide 1: IQVIA Research Forum 2022
IQVIA Research Forum 2022 P a t h w a ys a n d P r i o r i t i e s f o r H i g h I m p a c t Health Research October 2022 Copyright © 2019 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.
Slide 2: IQVIA Institute for Human Data Science contributes to advancing human health
IQVIA Institute for Human Data Science contributes to advancing human health by generating rigorous, evidence-based research PROPRIETARY DATA SOURCES* LIBRARY OF REPORTS EVIDENCE- SUBJECT MATTER EXPERTS BASED RESEARCH CONFERENCES ADVANCED ANALYTICAL SKILLS AND FORUMS THIRD PARTY INFORMATION PEER-REV
Slide 3: Support for academic researchers
Support for academic researchers How researchers can benefit from IQVIA data IQVIA data assets frequently used in academic research Through collaboration with the IQVIA Institute, Formulary Impact Analyzer: Pharmacy claims with insight into paid, rejected researchers have access to a broad range of
Slide 4: Five key themes
Five key themes Incorporating Navigating the Elevating the Exploring the complexity the impact of value to Charting the elusive nature and social of applied patients of future of high determinants heterogeneity research in of patient academic impact health on outcomes national health affordability h
Slide 5: Speakers
Speakers Session 1 Session 2 Kao-Ping Chua, Ph.D., MD Inmaculada Hernandez, PharmD, Ph.D. Assistant Professor, Dept of Pediatrics; Associate Professor, Division of Clinical Assistant Professor Health Management Pharmacy, Skaggs School of Pharmacy and Policy, University of Michigan School and Pharmac
Slide 6: Session 1: Exploring the elusive nature of applied research in national health crises
Session 1: Exploring the elusive nature of applied research in national health crises 5
Slide 7: Day 1, Session 1: Exploring the Elusive Nature of Applied Research in National Health Crises
Day 1, Session 1: Exploring the Elusive Nature of Applied Research in National Health Crises Operational Challenges Learning from Research – Data and Methodology Opioid Determining most effective Epidemic Integrating multiple data assets research in national crises COVID-19 Antimicrobial Prioritizin
Slide 8: Challenges of Conducting Timely, High-Quality Health Care Studies During the COVID-19 Pandemic
Challenges of Conducting Timely, High-Quality Health Care Studies During the COVID-19 Pandemic Kao-Ping Chua, MD, PhD Assistant Professor of Pediatrics Susan B. Meister Child Health Evaluation and Research Center Assistant Professor of Health Management and Policy University of Michigan School of Pu
Slide 9: Two key research challenges during COVID-19
Two key research challenges during COVID-19 • Data lag: time between the date that data arose and the date that researchers could access them • Publication lag: time between manuscript submission and publication
Slide 10: Many healthcare databases have long lag times
Many healthcare databases have long lag times • Claims databases: 1-3 years • National surveys (e.g., Medical Expenditure Panel Survey) and discharge databases (e.g., Nationwide Inpatient Sample) – 2 years
Slide 11: Implications of data lag
Implications of data lag • Many early studies of healthcare during the pandemic were single-center • Tradeoff between timeliness and quality
Slide 12: Implications of data lag
Implications of data lag • Many early studies of healthcare during the pandemic were single-center • Tradeoff between timeliness and quality • Temptation to publish preliminary data on COVID-19-related changes, rather than wait for more data
Slide 13: Proportion of families with at least one death of an adult from any cause
Proportion of families with at least one death of an adult from any cause 20- 10- Number per 100,000 families 0- ' + ' ' ' + 9 ' ' 1 1 1 ' 1 1 1 Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan I im 11 im im | 2016 2017 2018 2019 2020 MICHIGAN MEDICINE UNIVERSITY O
Slide 14: Proportion of families with at least one death of an adult from any cause
Proportion of families with at least one death of an adult from any cause 20- ; 10- Number per 100,000 families 0- ' ¢ 1 ' ' 1 + ' ' 1 © ' ' 1 + ' t+ ' ' 1 1 ' 1 1 Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan Apr Jul Oct Jan L i i 1 1 1 i} ' 2016 ' 2017 ' 2018
Slide 15: Initiatives to increase access to timely data faced implementation challenges
Initiatives to increase access to timely data faced implementation challenges • COVID-19 Research Database • Consortium of major health data companies deposited data into enclave and allowed free access • Delays associated with gaining access to data and exporting results • IQVIA Human Data Science
Slide 16: Summary
Summary • Many traditional data sources had too long of a lag to be useful during the pandemic • Real-time data were difficult to access despite stakeholder efforts • Need a nimbler method to get these data in the hands of researchers
Slide 17: Publication lag
Publication lag • Typical time between submission and publication if manuscript isn’t rejected by the first journal: 4-6 months • Much longer if manuscript is rejected
Slide 18: Implications of publication lag
Implications of publication lag • Increased use of pre-print servers • Tradeoff between timeliness and quality • Errors resulted in false narratives in the media • Tradeoff between immediate impact and academic advancement • Pre-prints don’t count towards promotion • Many journals do not publish man
Slide 19: Out-of-pocket costs for COVID-19 hospitalization
Out-of-pocket costs for COVID-19 hospitalization • In 2020, almost all insurers waived cost-sharing for COVID-19 hospitalization, but many started abandoning waivers in early 2021 • Question: how much would patients pay for COVID-19 hospitalizations without cost- sharing waivers? • Analysis of IQVIA
Slide 20: Article usage: May 2021 to September 2022
Article usage: May 2021 to September 2022 BM) Yale medRyiv ‘THE PREPRINT SERVER FOR HEALTH SCIENCES ‘Show by month Abstract Total 7.047 Picked up by 86 news outlets Blogged by 2 Out-of-Pocket Spending for COVID-19 Hospitalizations in 2020 | Tweeted by 37 See more details © Kao-Ping Chua, @ Rena M. C
Slide 21: Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations
Views 8,479 | Citations 6 | Altmetric 268 =) Download PDF y) (£) More & CME & MOC (@) Cite This © Permissions XX Original Investigation | Health Policy & October 18, 2021 Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020 Kao-Ping Chua, MD, PhD!:; Rena M. Conti, PhD
Slide 22: Summary
Summary • Need to align academic incentives with the timely dissemination of data • Academic promotions committees could consider high-impact, non-peer-reviewed products • Journals could adopt a policy that doesn’t penalize pre-prints (despite possibly decreased media attention)
Slide 23: Thank you
Thank you E-mail: chuak@med.umich.edu @kaopingchua
Slide 24: The Elusive Nature of Applied Research in National Health Crises
The Elusive Nature of Applied Research in National Health Crises: Antibiotics, Opioids, and COVID-19. Katie J. Suda, PharmD, M.S. Professor of Medicine, Pharmacy & Therapeutics, and Clinical & Translational Sciences University of Pittsburgh School of Medicine Director, Transition to Independence Pro
Slide 25: Disclosures
Disclosures • I have no actual or potential conflicts of interest in relation to this presentation. • I have received or am currently receiving research funding from AHRQ, CDC, FDA, NIH, and VA HSR&D, VA RR&D, and VA QUERI programs. • Opinions expressed today are those of the presenter and do not re
Slide 26: Every hour of every day
Every hour of every day….. 3 US persons die 3 US persons die of an infection 5 US persons die of Clostridioides caused by an of an opioid- difficile infection antibiotic-resistant related overdose. (CDI). pathogen. How can national data inform these public health challenges?
Slide 27: CDC: Monitor trends in opioid Rx
CDC: Monitor trends in opioid Rx. IQVIA Xponent. 2012 2020 High Rx Injury Center. CDC. Available at: https://www.cdc.gov/drugoverdose/rxrate-maps/index.html#print. Accessed October 2, 2022.
Slide 28: Specific specialty: Dental opioids
Specific specialty: Dental opioids. IQVIA LRx. No change No change Yan CH, et al. Am J Prev Med. 2022;63(1):3-12.
Slide 29: CDC: COVID-19 and antibiotic use
CDC: COVID-19 and antibiotic use. IQVIA Total Patient Tracker, CDC NHSN AU option. Retail Acute Care CDC. Antibiotic Use in the United States, 2020 Update: Progress and Opportunities. Atlanta, GA: US DHS, CDC; 2021. King LM, et al. Clin Infect Dis. 2021;73:e652-e660. Suda KJ, et al. Antimicrob Agent
Slide 30: Assess Overprescribing
Assess Overprescribing • 1 in 3 antibiotics prescribed in primary care are unnecessary (NAMCS, Marketscan) • RTI antibiotic: Urgent care > ED > ambulatory care clinics > retail clinics • 1 in 3 dental opioids are overprescribed (Marketscan) • Within health-systems, Black Medicare beneficiaries recei
Slide 31: Equitable distribution: Anti-infectives
Equitable distribution: Anti-infectives. IQVIA MIDAS. Suda KJ, et al. J Am Pharm Assoc. 2022;62:766.744. Khouja T, et al. J Antimicrob Chemother. 2022;77:1491-1499. Purchasing Rate – Developed Countries Purchasing Rate – Developing Countries Purchases for anti-infectives increased in developed count
Slide 32: Equitable distribution: Opioids
Equitable distribution: Opioids. IQVIA MIDAS. Gomes T, et al. Pharmacoepi Drug Saf. 2022;31:779-787. Tramadol Developed Codeine countries – Hydrocodone Oxycodone 24% decrease Developing Codeine countries – Tramadol 15% increase
Slide 33: Key messages
Key messages • Data is critical to address public health crises, target messaging to key groups, and inform interventions locally and nationally. • The ideal data source is at the population-level with ability for granular geographic areas, near real-time, with prescriber, patient, and visit-level c
Slide 34: Thank you
THANK YOU. ksuda@pitt.edu @SUDAmonas
Slide 35: Buprenorphine for Opioid Use Disorder in the Pandemic: The Dog that Didn't Bark?
Buprenorphine for Opioid Use Disorder in the Pandemic: The Dog that Didn’t Bark? Brendan Saloner, Ph.D. Johns Hopkins Bloomberg School of Public Health
Slide 36: Detective Gregory and Holmes quote
Detective Gregory: “Is there any other point to which you would wish to draw my attention?” Holmes: “To the curious incident of the dog in the night-time.” Gregory: “The dog did nothing in the night-time.” Holmes: “That was the curious incident.”
Slide 37: Buprenorphine for Opioid Use Disorder (OUD)
Buprenorphine for Opioid Use Disorder (OUD) • Most commonly used among the three major medications for opioid use disorder (methadone, buprenorphine, naltrexone) • Highly regulated under federal controlled substance laws (e.g., can only be prescribed by clinicians with a special license) • Optimally
Slide 38: What we expected to happen
What we expected to happen… • In March 2020, rapid onset of stay at home orders were seen as an imminent threat to people with chronic disease • Pre-pandemic most patients on buprenorphine for OUD were dependent on monthly visits to their prescriber + counseling sessions • Discontinuation of bupreno
Slide 39: But there was a rapid federal response
…but there was a rapid federal response • Flexibility around telehealth for prescribers, shift to virtual counseling, decreased required urine testing
Slide 40: Aggregate Analysis of Buprenorphine During the Early Pandemic Months
Aggregate Analysis of Buprenorphine During the Early Pandemic Months • Aggregate analysis of trends using Symphony Health data from May 1, 2019 to June 28, 2020 • Comparison of buprenorphine fill quantities versus all filled prescriptions • Test for differences in trends pre- versus post-pandemic
Slide 41: Assessment of filled buprenorphine prescriptions during COVID-19
Nguyen, T. D., Gupta, S., Ziedan, E., Simon, K. I., Alexander, G. C., Saloner, B., & Stein, B. D. (2021). Assessment of filled buprenorphine prescriptions for opioid use disorder during the coronavirus disease 2019 pandemic. JAMA internal medicine, 181(4), 562-565.
Slide 42: Was the Stability in Buprenorphine Fills Experienced by All Groups?
Was the Stability in Buprenorphine Fills Experienced by All Groups? • Follow-up analysis using fill-level data from IQVIA provided through Human Data Science Research Collaborative • We estimate multilevel models (patient, prescriber, ZIP, region) for risk of discontinuation in each of two time peri
Slide 43: Discontinuation rate decreased from 2019 to 2020
Discontinuation rate decreased from 2019 to 2020, and predictors were very similar • 15.7% discontinued in 2019 versus 14.0% in 2020 • Strongest predictors of discontinuation in both time periods: younger age (versus older), lower volume prescribers and PA/NP • New England states had notably lower d
Slide 44: Percent of Patients Stopping Buprenorphine in May-August
Percent of Patients Stopping Buprenorphine in May-August 10% 20% 30% 40% 50% 60% 70% 0% 0.01 0.03 0.05 0.07 0.09 0.11 0.13 0.15 0.17 0.19 0.21 0.23 0.25 0.27 0.29 0.31 0.33 0.35 0.37 0.39 0.41 0.43 2019 0.45 0.47 0.49 0.51 0.53 2020 0.55 Prescriber Percentile 0.57 0.59 0.61 0.63 0.65 0.67 0.69 0.71
Slide 45: Percent of Patients Stopping Buprenorphine in May-August
Percent of Patients Stopping Buprenorphine in May-August 10% 20% 30% 40% 50% 60% 70% 0% 0.01 0.03 0.05 0.07 0.09 0.11 0.13 0.15 0.17 0.19 0.21 0.23 2019 0.25 0.27 0.29 0.31 2020 0.33 % of patients who discontinue 0.35 0.37 0.39 0.41 0.43 2019 0.45 0.47 0.49 0.51 0.53 2020 0.55 Prescriber Percentile
Slide 46: Was Buprenorphine Use the Dog that Didn't Bark in the Pandemic?
Was Buprenorphine Use the Dog that Didn’t Bark in the Pandemic? • The remarkable continuity of treatment for buprenorphine patients defied expectations that treatment would fall of rapidly • Continuity likely due to the success of federal provisions • A policy paradox: Stability during a time of str
Slide 47: Some important caveats
Some important caveats • Stability for new patients may not be the full story – we still need to understand what happened to people who were not yet in the system • Overall, access to buprenorphine is not meeting the urgency of the national overdose crisis
Slide 48: Thank you!
Thank you! References: Nguyen TD, Gupta S, Ziedan E, Simon KI, Alexander GC, Saloner B, Stein BD. Assessment of filled buprenorphine prescriptions for opioid use disorder during the coronavirus disease 2019 pandemic. JAMA internal medicine. 2021 Apr 1;181(4):562-5. Saloner B, Chang HY, Alexander GC,
Slide 49: Panel Discussion
Panel Discussion Presenters Kao-Ping Chua Katie Suda Brendan Saloner Assistant Professor Professor of Medicine Associate Professor University of Michigan School of University of Pittsburgh Department Department of Health Policy and Public Health of Medicine Management, Johns Hopkins Bloomberg School
Slide 50: Q&A
Q&A Post your questions and comments in the Q&A box. 49
Slide 51: Session 2: Incorporating the impact of social determinants on outcomes in healthcare research
Session 2: Incorporating the impact of social determinants on outcomes in healthcare research 50
Slide 52: IQVIA Research Forum agenda
IQVIA Research Forum agenda Incorporating Navigating the Elevating the Exploring the complexity the impact of value to Charting the elusive nature and social of applied patients of future of high determinants heterogeneity research in of patient academic impact health on outcomes national health aff
Slide 53: Incorporating the impact of social determinants on outcomes in healthcare research
Incorporating the impact of social determinants on outcomes in healthcare research Overview The social determinants of health – income, education, housing, work, food, and other social and environmental conditions– is of growing importance in healthcare research when understanding the impact of non-
Slide 54: Integrating non-traditional data sources to study the impact of social determinants on health outcomes
Integrating non-traditional data sources to study the impact of social determinants on health outcomes Susan dosReis, PhD Professor & Vice Chair for Research University of Maryland School of Pharmacy October 10, 2022
Slide 55: Impact of Diverse Social Determinants
Impact of Diverse Social Determinants Health outcomes are impacted by multi-stakeholder interactions Healthcare Policies (consumers, providers, policy Medication Quality Benchmarks Care Coordination makers) in diverse settings Healthcare Access Crime Housing Internet Access Area Deprivation Index Me
Slide 56: Measures of Social Determinants
Measures of Social Determinants Area Deprivation Index Indicators of Socioeconomic Disadvantage Domain Area Deprivation Measure Median family income Income disparity Percent of families below the poverty level Percent of the population <150% poverty threshold Poverty Percent single parent households
Slide 57: Social Determinants and Policy Effects in Vulnerable or Underserved Populations
Social Determinants and Policy Effects in Vulnerable or Underserved Populations Optimized Hot Spot Analysis & Youth in Zipcode Tabulation Area (ZCTA) Cold Percent Change in Psychotropic and Antipsychotic Prevalence by Hot, Cold, and Neutral Spots of Deprivation Hot Cold Neutral Hot Psychotropic Over
Slide 58: Practical Considerations
Practical Considerations • Need for granular data at each level to better assess the impact of social determinants • Link social determinants across the multiple levels • Define endpoints across the spectrum of social determinants
Slide 59: Practical considerations for the study of social determinants of health in large administrative data
Practical considerations for the study of social determinants of health in large administrative data October 10, 2022 Inmaculada (Inma) Hernandez, PharmD, PhD, FACC, FAHA Associate Professor of Clinical Pharmacy Skaggs School of Pharmacy and Pharmaceutical Sciences UC, San Diego inhernandez@health.u
Slide 60: Social determinants of health
Social Our Comparative Effectiveness Research on Acknowledgements & Determinants of Health AnticoagulantsDisclosures Social determinants of health (SDoH) • The conditions in which people are born, grow, live, work and age • Critical to capture individual-level AND neighborhood-level factors in SDoH
Slide 61: Practical challenges (I)
Ourchallenges Comparative Practical Practical (I) Effectiveness Acknowledgements challenges (I) Research & on AnticoagulantsDisclosures Related to data sources • Comprehensive datasets capture highly specific population segments • Underrepresentation of individuals without insurance, with intermitte
Slide 62: Practical challenges (II)
Ourchallenges Comparative Practical Practical (II) Effectiveness Acknowledgements challenges (II) Research & on AnticoagulantsDisclosures Neighborhood-level factors • Low granularity of patient-level address information • Available geographic units are often: • Large and heterogeneous • Not linkable
Slide 63: Recommendations
Our Comparative Effectiveness Research Acknowledgements Recommendations Recommendations & on AnticoagulantsDisclosures ✓Need to re-envision data security standards to enable SDoH research while maintaining highest-levels of data protection ✓Need to work on the development of nationwide data reposito
Slide 64: Structural Racism and Health Equity Research: Evidence Needed to Address Disparities in Access to Medicines
Structural Racism and Health Equity Research: Evidence Needed to Address Disparities in Access to Medicines Dima M Qato, MPH, PharmD, PhD Hygeia Centennial Chair and Associate Professor of Pharmacy Senior Fellow, Schaeffer Center for Health Policy and Economics University of Southern California @dim
Slide 65: Structural racism is a fundamental cause of SDoH and health disparities
Structural racism is a fundamental cause of SDoH and health disparities Braveman P, Gottlieb L. Public Health Reports.
Slide 66: Structural Racism as a fundamental cause of disparities in access to medicines
Structural Racism as a fundamental cause of disparities in access to and use of medicines in the U.S. Structural Racism (Federal, state, local health policies and practices) Racial/Ethnic residential Geographic Variation in Pharmacy Systems and Affordability of Segregation Services Prescription Med
Slide 67: Challenges to incorporate measures of structural racism in health equity research
Challenges to incorporate measures of structural racism in health equity research o Lack of clarity on definitions/measures of structural racism in the context of health policy → access to medicines • Residential racial/ethnic segregation (neighborhood-level) • How about structural racism within Med
Slide 68: Pharmacy Deserts and Closures in Chicago
Pharmacy Pharmacy Deserts and Closures in Chicago Worsened in Access Segregated Black and Latinx Neighborhoods Since 2015
Slide 69: Implications of failing to incorporate structural racism in health equity research
What are the implications of failing to incorporate structural racism in health equity research? o Perpetuate structural racism within health systems and policies that contribute to persistent, worsening Inequitable access to essential medicines in Black and Hispanic populations in the U.S. 1. We kn
Slide 70: Opportunities for research to inform evidence-based policies
Opportunities for research to inform evidence-based policies that reduce, not worsen, inequitable access to medicines o Develop and integrate measures in available data sources that have the potential to change existing policies AND promote racial equity • Promote accountability→ Who is responsible
Slide 71: Panel Discussion
Panel Discussion Presenters Susan dosReis Inmaculada Hernandez Dima Qato Professor Associate Professor Associate Professor University of Maryland School of UC San Diego Skaggs School of University of Southern California Pharmacy Pharmacy and Pharmaceutical School of Pharmacy Sciences 70
Slide 72: Q&A
Q&A Post your questions and comments in the Q&A box 71
Slide 73: IQVIA Research Forum agenda
IQVIA Research Forum agenda Incorporating Navigating the Elevating the Exploring the complexity the impact of value to Charting the elusive nature and social of applied patients of future of high determinants heterogeneity research in of patient academic impact health on outcomes national health aff
Slide 74: Thank you
IQVIA INSTITUTE FOR HUMAN DATA SCIENCE Thank you
Slide 75: Download featured Institute content
Download featured Institute content www.IQVIAInstitute.org Find us on social media Twitter: @IQVIA_Institute LinkedIn: #IQVIAInstitute 74
Slide 76: Thank you
Thank you Global Trends in R&D: Overview through 2020. Report by the IQVIA Institute for Human Data Science.